Abstract P6-18-31: PROCLAIM-CX-072: Monotherapy for advanced triple negative breast cancer with skin metastases in a phase 1-2 trial of the PD-L1 probody therapeutic CX-072
Year: 2019
Type: conference-abstract
Source: Cancer Research
Authors: S Adams, E Hamilton, PA Ott, D Cho, K Kalinsky, P LoRusso, M Will, V Huels, B Benson, C Murias, H-T Arkenau
Institutions: Harvard University, Sarah Cannon Research Institute, Columbia University Irving Medical Center, Yale Cancer Center, Yale University, NYU Langone Health, Sarah Cannon, Dana-Farber Cancer Institute, Tennessee Oncology, CytomX Therapeutics (United States), NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2944744217